---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-26-008465"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2026-06-03T20:17:06+00:00"
generated_at: "2026-06-03T20:48:20.642118+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics: LOTIS-5 Phase 3 meets PFS endpoint; sBLA submission planned Q4 2026

## Summary
- PFS HR=0.73 (p=0.008); median PFS 6.1 mo ZYNLONTA+ritux vs 4.7 mo R-GemOx.
- ORR 58.1% vs 45.2%; CR 39.5% vs 26.7%; median DoCR 16.8 vs 12.3 mo.
- Grade 5 TEAEs higher in test arm (13.2% vs 4.6%); majority in patients ≥75 years.
- Plans pre-sBLA meeting with FDA in August; sBLA submission expected Q4 2026.
- Company will evaluate value-maximizing alternatives, including cost reduction initiatives.

## SEC filing metadata
- accession: 0000950103-26-008465
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2026-06-03T20:17:06+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000095010326008465/0000950103-26-008465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000095010326008465/dp247928_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-26-008465
- JSON: https://secwatch.observer/filing/0000950103-26-008465.json
- Plain text: https://secwatch.observer/filing/0000950103-26-008465.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.